The Association between White Blood Call with CD59 Expression upon surface in Peripheral blood and Therapeutic Response to Anti-CD20 Antibody in B-Non Hodgkin’s Lymphoma
Article Sidebar
Main Article Content
Abstract
Background: Although Rituximab is effective treatment for B-cell non-Hodgkin lymphoma, the exact mechanism of its antitumor effect is unclear. One potential mechanism involves complement-mediated cytotoxicity. The usage of rituximab should be considerably selected because it is vary expensive. Objective: To assess the association between expressions of CD59 on white blood cell surface in peripheral blood and outcome after chemotherapy in combination with rituximab treatment in B-cell non-Hodgkin lymphoma patients. Patients & Methods: Patients with B-cell non-Hodgkin lymphoma who received treatment with rituximab plus chemotherapy at King Chulalongkorn Memorial Hospital from August 2001 to October 2002 who gave informed consent, were recruited to the study. The patients had received physical examination, blood test, radiographic examination, bone marrow study and the expression of CD59 on white blood cell surface in peripheral blood was determined by flow cytometry before rituximab treatment. Patients were classified as achieved complete responses (CR) or no compete response after complete treatment. Result: A total of 47 B-cell NHL patients were included in the study. The median age of the patents was 53 ± SD year (range 20-77). The histology subtypes were diffuse large B-cell follicular small cleave, and small lymphocytic 89.4%, 8.5% and 2.1%, respectively. The frequencies of patients in low, low-intermediate, high-intermediate and high risk groups according to the international prognostic index were 8.5%, 19.1%, 29.8% and 42.6%, respectively. Twenty-five patients (53.2%) received rituximab plus CHOP. Thirty-six patients achieved complete responses (CR), 11 patients obtained no CR. Mean CD59 level were not significantly higher in non CR group than in CR group (55.3%, 40.57%) (P-value=0.13). Conclusion: Expression of CD59 on white blood cell surface in peripheral blood dose not predict clinical outcome after rituximab treatment in B-cell non-Hodgkin lymphoma.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Intragumtornchai T, Wannakrairoj P, Chaimongkol B, Bhoopat L, Lekhakula A, Thamprasit T, T, et al. Hodgkin's lymphomas inretrospective pathologic and clinical analysis of 1391 cases. Cancer 1996; 78:1813-9.
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's Iympboma. N Engl J Med 1993; 328:1002-6.
The International nou-Hodgkin's lymphoma Prognosnoshosic Factor project. A predictive model for aggressive nonHodgkin's lymphoma. N Eng! I Med 1993; 129:987-93.
Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SE, Nadler L.M. Expression of human B cellassociated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63: 1424-33.
Maloney DG, Liles T'M, Czerwinski DK, Waldichuk C, Rosenberg J, Grilo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti CD 20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-66.
Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al. IDEC-C2B8: results of a phasc I multiple-dose trial in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 1997; 15:3266-74.
Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anti-cancer therapy using nituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma Biochem Soc Trans 1997; 25: 705-8.
Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri Giri Git Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell cell lysis. Blood 2000; 95: 3900-8.
Frixos P. Cluster of differentiation. In: Richard G, Foerster J, Lukens J, Gree J, Rodger G, Paraskevas F, editors. Wintrobe's Clinical Hematology. 10th ed. Baltimore: Williams and Wiltkins 1999; p 72-97.
McLaughlin P,Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program. J Clin Oncol. 1998; 16: 2825-33.Maloney DG,Press OW.Newer treatments for non-Hodgkin's lymphoma:Monoclonal antibodics. Oncology 1998; 12: 63-76.
Czuczman MS, Grillo-Lopez AJ, McLaughlin P, White CA, Salch M, Gordon LI, et al. Treatment of patients with low -grade B-cell Iymphoma with the combination of chimeric anti-CD20 monoclonal antibody (Rituzan, Rituximab) and CHOP chemotherpay. J Clin Oncol 1999; 17: 767-71.
Coitfier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 2002;346: 235-42.
Intragumtornchai T, Rojnuchkarin P, Bunworasate P. Rituximab plus CHOP and ESHAP in patients with high- intermediate risk and high-risk aggressive non Hodgkin's lymphoma (Abstract). Hematol J 2003; 4 (Suppl2): 93.
Carbone PP, Kaplan HS, Musshoff K. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1.
Ken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and Response Criteria of The Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
Almasri NM, Dugue RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic Iymphocytic leukemia. Am Hematol 1992; 40: 259-63.
Bannerji R, Pearson M. Flinn TW, Kitada S, Young D, Reed JC, et al. Cell surface complement inhibitors CD55 and CD59 may mediate chronic lymphocytic leukemia (CLL) resistance to rituximab therapy [abstract). Blood 2000; 96: 164.